VYGR Voyager Therapeutics, Inc.
Listings ·
Voyager Therapeutics' stockholders approved on June 9, 2026 an increase in authorized common stock from 120,000,000 to 240,000,000 shares, and in total authorized capital stock from 125,000,000 to 245,000,000. The 8-K gives no reason for the increase.
We have not published a story on Voyager Therapeutics yet. When there is news, it will appear here.
Voyager Therapeutics, Inc. is a biotechnology company that aims to leverage human genetics to modify the course of and ultimately cure neurological diseases. Many of its programs derive from its TRACER AAV capsid discovery platform, which identifies capsids with robust blood-brain barrier penetration after intravenous dosing. Its wholly owned pipeline focuses on Alzheimer's disease with two tau-targeting programs. VY1706 is a tau silencing gene therapy that uses an intravenously delivered TRACER capsid containing a vectorized small interfering RNA, and the company expects to submit an investigational new drug application in the second quarter of 2026. VY7523 is an IV-administered anti-tau antibody in a Phase 1 multiple ascending dose trial in early Alzheimer's disease patients, initiated in February 2025. Partnered programs include frataxin and GBA1 gene therapies with Neurocrine Biosciences, a program with Transition Bio on selective small molecules for amyotrophic lateral sclerosis and frontotemporal dementia with TDP-43 pathology, and capsid collaborations with Novartis and Alexion. The text says partnerships have delivered more than $500.0 million in non-dilutive funding to date.
| Product or program | What it is | Stage |
|---|---|---|
| VY1706 | Tau silencing gene therapy for Alzheimer's disease | IND submission anticipated in second quarter of 2026 |
| VY7523 | IV-administered anti-tau antibody for Alzheimer's disease | Phase 1 multiple ascending dose trial, initiated February 2025 |
| NBIB-’223 (FA Program) | Frataxin gene therapy for Friedreich's ataxia, partnered with Neurocrine | Neurocrine intends to start a trial in second half of 2026, pending IND clearance |
| GBA1 Program | GBA1 gene therapy for Gaucher disease and Parkinson's disease, partnered with Neurocrine | |
| Transition Bio small molecules | Selective small molecules for ALS and frontotemporal dementia with TDP-43 pathology | |
| Voyager NeuroShuttle | Non-viral platform for transporting neurotherapeutics across the blood-brain barrier |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $134.7 million | $127.4 million |
| Net income (loss) | -$119.7 million | -$65.0 million |
| Cash from operations | -$132.5 million | -$15.3 million |
| Cash and equivalents | $65.3 million | $71.4 million |
| Short-term investments | $131.1 million | $195.3 million |
Voyager Therapeutics, Inc. trades under the ticker VYGR on NASDAQ.
Voyager Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:VT6; LS:A143XJ.
The SEC Central Index Key (CIK) for Voyager Therapeutics, Inc. is 1640266. Its filings are on SEC EDGAR.
61,617,948 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Voyager Therapeutics, Inc. under United States.
Our directory classifies Voyager Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Voyager Therapeutics, Inc. is US92915B1061.
aibio.space lists Voyager Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Voyager Therapeutics, Inc. is a biotechnology company that aims to leverage human genetics to modify the course of and ultimately cure neurological diseases. Many of its programs derive from its TRACER AAV capsid discovery platform, which identifies capsids with robust blood-brain barrier penetration after intravenous dosing.
VY1706: Tau silencing gene therapy for Alzheimer's disease Stage: IND submission anticipated in second quarter of 2026.
VY7523: IV-administered anti-tau antibody for Alzheimer's disease Stage: Phase 1 multiple ascending dose trial, initiated February 2025.
Voyager Therapeutics, Inc. reported a net loss of $119.7 million for the fiscal year ended Dec 31, 2025, and used $132.5 million of cash in operations, per its annual report to the SEC.
$134.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
$116.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio